<?xml version="1.0" encoding="UTF-8"?>
<drug type="biotech" created="2017-09-08" updated="2019-12-02">
  <drugbank-id primary="true">DB13892</drugbank-id>
  <name>Crotalus atrox antivenin</name>
  <description>Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species. The majority of people bitten are males and about 50% occur in the age group of 18 to 28 [F113].&#13;
&#13;
Crotalus atrox antivenin is derived and purified immunoglobulin fragments obtained from other domestic animals such as sheep previously immunized with Crotalus atrox (Western Diamondback rattlesnake). Bites from this snake are the most common in the state of Texas, USA [A33157]. &#13;
&#13;
The final purified antivenin product is produced by mixing other different monospecific snake antivenins and isolating the antivenin of interest through fractionation and chromatography techniques. It is intravenously (IV) administered to prevent/limit systemic toxicity [FDA label].</description>
  <cas-number/>
  <unii>RBR61YAJ4V</unii>
  <groups>
    <group>approved</group>
    <group>experimental</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A33155</ref-id>
        <pubmed-id>9839686</pubmed-id>
        <citation>de Rezende NA, Torres FM, Dias MB, Campolina D, Chavez-Olortegui C, Amaral CF: South American rattlesnake bite (Crotalus durissus SP) without envenoming: insights on diagnosis and treatment. Toxicon. 1998 Dec;36(12):2029-32.</citation>
      </article>
      <article>
        <ref-id>A33156</ref-id>
        <pubmed-id>9209225</pubmed-id>
        <citation>Seifert SA, Boyer LV, Dart RC, Porter RS, Sjostrom L: Relationship of venom effects to venom antigen and antivenom serum concentrations in a patient with Crotalus atrox envenomation treated with a Fab antivenom. Ann Emerg Med. 1997 Jul;30(1):49-53.</citation>
      </article>
      <article>
        <ref-id>A33157</ref-id>
        <pubmed-id>10613947</pubmed-id>
        <citation>Rosen PB, Leiva JI, Ross CP: Delayed antivenom treatment for a patient after envenomation by Crotalus atrox. Ann Emerg Med. 2000 Jan;35(1):86-8.</citation>
      </article>
      <article>
        <ref-id>A33158</ref-id>
        <pubmed-id>6367819</pubmed-id>
        <citation>Pandya BV, Budzynski AZ: Anticoagulant proteases from western diamondback rattlesnake (Crotalus atrox) venom. Biochemistry. 1984 Jan 31;23(3):460-70.</citation>
      </article>
    </articles>
    <textbooks/>
    <links>
      <link>
        <ref-id>L2864</ref-id>
        <title>Delayed antivenom treatment for a patient after envenomation by Crotalus atrox</title>
        <url>https://www.sciencedirect.com/science/article/pii/S0196064400701119</url>
      </link>
      <link>
        <ref-id>L2868</ref-id>
        <title>CROFAB.COM</title>
        <url>https://www.crofab.com/Treatment-With-CroFab/What-is-CroFab</url>
      </link>
      <link>
        <ref-id>L2873</ref-id>
        <title>Epocrates online, Crofab</title>
        <url>https://online.epocrates.com/u/1073686/CroFab/Pharmacology</url>
      </link>
      <link>
        <ref-id>L2874</ref-id>
        <title>Drugs.com, Crofab</title>
        <url>https://www.drugs.com/monograph/crofab.html</url>
      </link>
    </links>
    <attachments>
      <attachment>
        <ref-id>F112</ref-id>
        <title>Crotalus atrox PhospholipaseAz</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/112/original/J._Biol._Chem.-1982-Randolph-2155-61.pdf?1527201766</url>
      </attachment>
      <attachment>
        <ref-id>F113</ref-id>
        <title>Crotalidae Polyvalent Immune Fab (Ovine)</title>
        <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/000/113/original/Crotalidae_Polyvalent_Immune_Fab_%28Ovine%29_%28PDF_Download_Available%29.pdf?1527201938</url>
      </attachment>
    </attachments>
  </general-references>
  <synthesis-reference/>
  <indication>CROFAB is indicated for the management of adult and pediatric patients with North American crotalid envenomation. The term crotalid is used to describe the Crotalinae subfamily (formerly known as Crotalidae) of venomous snakes which includes rattlesnakes, copperheads and cottonmouths/water moccasins [FDA label].</indication>
  <pharmacodynamics>Crotalus atrox venom contains agents that render human fibrinogen and plasma incoagulable by thrombin [A33158].   CROFAB antivenom reverses these effects [FDA label].&#13;
&#13;
This facilitates re-distribution of venom toxins away from target tissues and elimination from the body [L2874].&#13;
&#13;
It is a mixture of 4 different monospecific antivenoms derived from serum of healthy sheep immunized with one of the following North American snake venoms: C. atrox (Western diamondback rattlesnake), C. adamanteus (Eastern diamondback rattlesnake), C. scutulatus (Mojave rattlesnake), or A. piscivorus (cottonmouth or water moccasin) [L2874].&#13;
</pharmacodynamics>
  <mechanism-of-action>CROFAB consists of venom-specific Fab fragments of immunoglobulin G (IgG) that work by binding to and neutralizing venom toxins, facilitating their redistribution away from target tissues and their elimination from the body [L2868].&#13;
&#13;
CROFAB contains only the Fab fragments from ovine-derived immunoglobulins. The enzyme _papain_ is used to cleave the IgG antibody, creating 2 separate Fab fragments and 1 Fc fragment. After the cleavage step, another protein binds to the Fc fragments, which are not essential for binding snake venom, allowing the pure Fab fragments to be recovered.The Fab fragments of an immunoglobulin  contain the variable regions that recognize and bind to specific antigens [L2868].</mechanism-of-action>
  <toxicity>&#13;
Most common adverse reactions (incidence â‰¥5% of subjects) were urticaria, rash nausea, pruritus and back pain [FDA label].&#13;
&#13;
Severe hypersensitivity reactions may occur with the use of CROFAB. In case of acute hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions, discontinue infusion and institute appropriate emergency treatment [FDA label].&#13;
&#13;
CROFAB contains purified immunoglobulin fragments from the blood of sheep that have been immunized with snake venoms. Injection of heterologous animal proteins can lead to severe acute and delayed hypersensitivity reactions (late serum reaction or serum sickness) and a possible febrile response to immune complexes formed by animal antibodies and neutralized venom components.&#13;
&#13;
_Papain_  enzyme is used to cleave antibodies into fragments during the processing of CROFAB, and negligible amounts of papain or inactivated papain residues may be present. Patients allergic to papain, chymopapain, other papaya extracts, or the pineapple enzyme bromelain may also have an allergic reaction to CROFAB. Certain dust mite allergens and some latex allergens share antigenic structures with papain and patients with these allergies may be allergic to papain [FDA label].</toxicity>
  <metabolism/>
  <absorption/>
  <half-life>12-23 hours [F113]</half-life>
  <protein-binding/>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description/>
    <direct-parent>Peptides</direct-parent>
    <kingdom>Organic Compounds</kingdom>
    <superclass>Organic Acids</superclass>
    <class>Carboxylic Acids and Derivatives</class>
    <subclass>Amino Acids, Peptides, and Analogues</subclass>
  </classification>
  <salts/>
  <synonyms>
    <synonym language="english" coder="">Crotalus atrox immune fab antivenin (ovine)</synonym>
  </synonyms>
  <products>
    <product>
      <name>CroFab</name>
      <labeller>BTG International Inc.</labeller>
      <ndc-id/>
      <ndc-product-code>50633-110</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2000-02-10</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Injection, powder, lyophilized, for solution</dosage-form>
      <strength/>
      <route>Intravenous</route>
      <fda-application-number>BLA103788</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>CroFab</name>
      <ingredients>Agkistrodon piscivorus antivenin + Crotalus adamanteus antivenin + Crotalus atrox antivenin + Crotalus scutulatus antivenin</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Antivenin</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antivenins</category>
      <mesh-id>D000997</mesh-id>
    </category>
    <category>
      <category>Passively Acquired Immunity</category>
      <mesh-id/>
    </category>
    <category>
      <category>Venom Neutralization</category>
      <mesh-id/>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Humans</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Injection, powder, lyophilized, for solution</form>
      <route>Intravenous</route>
      <strength/>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB13892.pdf?1505427755</fda-label>
  <patents/>
  <food-interactions/>
  <drug-interactions/>
  <sequences/>
  <experimental-properties/>
  <external-identifiers>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>347911461</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes>
    <enzyme position="1">
      <id>BE0000070</id>
      <name>Group 10 secretory phospholipase A2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A185633</ref-id>
            <pubmed-id>9381655</pubmed-id>
            <citation>Walton RM, Brown DE, Hamar DW, Meador VP, Horn JW, Thrall MA: Mechanisms of echinocytosis induced by Crotalus atrox venom. Vet Pathol. 1997 Sep;34(5):442-9. doi: 10.1177/030098589703400508.</citation>
          </article>
          <article>
            <ref-id>A185636</ref-id>
            <pubmed-id>21392522</pubmed-id>
            <citation>Sanny CG: In vitro evaluation of total venom-antivenin immune complex formation and binding parameters relevant to antivenin protection against venom toxicity and lethality based on size-exclusion high-performance liquid chromatography. Toxicon. 2011 May;57(6):871-81. doi: 10.1016/j.toxicon.2011.03.003. Epub 2011 Mar 15.</citation>
          </article>
          <article>
            <ref-id>A185639</ref-id>
            <pubmed-id>22359435</pubmed-id>
            <citation>Perumal Samy R, Gopalakrishnakone P, Chow VT: Therapeutic application of natural inhibitors against snake venom phospholipase A(2). Bioinformation. 2012;8(1):48-57. doi: 10.6026/97320630008048. Epub 2012 Jan 6.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O15496" source="Swiss-Prot">
        <name>Group 10 secretory phospholipase A2</name>
        <general-function>Phospholipase activity</general-function>
        <specific-function>PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a powerful potency for releasing arachidonic acid from cell membrane phospholipids. Prefers phosphatidylethanolamine and phosphatidylcholine liposomes to those of phosphatidylserine.</specific-function>
        <gene-name>PLA2G10</gene-name>
        <locus>16p13.1-p12</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-31</signal-regions>
        <theoretical-pi>6.46</theoretical-pi>
        <molecular-weight>18153.04</molecular-weight>
        <chromosome-location>16</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9029</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PLA2G10</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>U95301</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2289237</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1422</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O15496</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PA2GX_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.1.4</synonym>
          <synonym>Group X secretory phospholipase A2</synonym>
          <synonym>GX sPLA2</synonym>
          <synonym>Phosphatidylcholine 2-acylhydrolase 10</synonym>
          <synonym>sPLA2-X</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0010149|Group 10 secretory phospholipase A2
MGPLPVCLPIMLLLLLPSLLLLLLLPGPGSGEASRILRVHRRGILELAGTVGCVGPRTPI
AYMKYGCFCGLGGHGQPRDAIDWCCHGHDCCYTRAEEAGCSPKTERYSWQCVNQSVLCGP
AENKCQELLCKCDQEIANCLAQTEYNLKYLFYPQFLCEPDSPKCD</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010150|Group 10 secretory phospholipase A2 (PLA2G10)
ATGGGGCCGCTACCTGTGTGCCTGCCAATCATGCTGCTCCTGCTACTGCCGTCGCTGCTG
CTGCTGCTGCTTCTACCTGGCCCCGGGTCCGGCGAGGCCTCCAGGATATTACGTGTGCAC
CGGCGTGGGATCCTGGAACTGGCAGGAACTGTGGGTTGTGTTGGTCCCCGAACCCCCATC
GCCTATATGAAATATGGTTGCTTTTGTGGCTTGGGAGGCCATGGCCAGCCCCGCGATGCC
ATTGACTGGTGCTGCCATGGCCACGACTGTTGTTACACTCGAGCTGAGGAGGCCGGCTGC
AGCCCCAAGACAGAGCGCTACTCCTGGCAGTGCGTCAATCAGAGCGTCCTGTGCGGACCG
GCAGAGAACAAATGCCAAGAACTGTTGTGCAAGTGTGACCAGGAGATTGCTAACTGCTTA
GCCCAAACTGAGTACAACTTAAAGTACCTCTTCTACCCCCAGTTCCTATGTGAGCCGGAC
TCGCCCAAGTGTGACTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00068</identifier>
            <name>Phospholip_A2_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phospholipase A2 activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phospholipase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>axon guidance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cholesterol homeostasis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycerophospholipid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lysophospholipid transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cholesterol efflux</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of sequence-specific DNA binding transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidic acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylcholine acyl-chain remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylethanolamine acyl-chain remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylglycerol acyl-chain remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol acyl-chain remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylserine acyl-chain remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of arachidonic acid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cellular protein metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of lipid storage</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of macrophage derived foam cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of prostaglandin secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of macrophage activation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>